Takeda Pharmaceutical Co. Ltd. Files Prospectus for $2.4 Billion in Guaranteed Notes Due 2035 and 2055

Reuters
02 Jul
Takeda Pharmaceutical Co. Ltd. Files Prospectus for $2.4 Billion in Guaranteed Notes Due 2035 and 2055

Takeda Pharmaceutical Co. Ltd. has filed a prospectus with the Securities and Exchange Commission as part of a Registration Statement on Form F-3, in collaboration with Takeda U.S. Financing, Inc. The filing includes the issuance of $1.65 billion in 5.200% Guaranteed Notes due 2035 and $750 million in 5.900% Guaranteed Notes due 2055. The respective opinions on these financial instruments have been provided by Sullivan & Cromwell LLP and Nishimura & Asahi (Gaikokuho Kyodo Jigyo). The indenture, dated July 2, 2025, involves Takeda Pharmaceutical as the guarantor, Takeda U.S. Financing as the issuer, and The Bank of New York Mellon in various trustee and agent roles. This financial move is part of Takeda's strategic financing efforts, as detailed in their recent Form 6-K submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001395064-25-000111), on July 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10